Lessons learned from radiation oncology clinical trials

Fei Fei Liu, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, Chandan Guha

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality and limitations of the preclinical data that supported the hypotheses underlying these trials, and to consider possible solutions to these challenges for the design of future clinical trials. Several themes emerged from the discussions: (i) opportunities to learn from null-hypothesis trials through tissue and imaging studies; (ii) value of preclinical data supporting the design of combinatorial therapies; (iii) significance of validated biomarkers; (iv) necessity of quality assurance in radiotherapy delivery; (v) conduct of sufficiently powered studies to address the central hypotheses; and (vi) importance of publishing results of the trials regardless of the outcome. The fact that well-designed hypothesis-driven clinical trials produce null or negative results is expected given the limitations of trial design and complexities of cancer biology. It is important to understand the reasons underlying such null results, however, to effectively merge the technologic innovations with the rapidly evolving biology for maximal patient benefit through the design of future clinical trials.

Original languageEnglish (US)
Pages (from-to)6089-6100
Number of pages12
JournalClinical Cancer Research
Volume19
Issue number22
DOIs
StatePublished - Nov 15 2013

Fingerprint

Radiation Oncology
Clinical Trials
Education
Radiotherapy
Biomarkers
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Liu, F. F., Okunieff, P., Bernhard, E. J., Stone, H. B., Yoo, S., Norman Coleman, C., ... Guha, C. (2013). Lessons learned from radiation oncology clinical trials. Clinical Cancer Research, 19(22), 6089-6100. https://doi.org/10.1158/1078-0432.CCR-13-1116

Lessons learned from radiation oncology clinical trials. / Liu, Fei Fei; Okunieff, Paul; Bernhard, Eric J.; Stone, Helen B.; Yoo, Stephen; Norman Coleman, C.; Vikram, Bhadrasain; Brown, Martin; Buatti, John; Guha, Chandan.

In: Clinical Cancer Research, Vol. 19, No. 22, 15.11.2013, p. 6089-6100.

Research output: Contribution to journalArticle

Liu, FF, Okunieff, P, Bernhard, EJ, Stone, HB, Yoo, S, Norman Coleman, C, Vikram, B, Brown, M, Buatti, J & Guha, C 2013, 'Lessons learned from radiation oncology clinical trials', Clinical Cancer Research, vol. 19, no. 22, pp. 6089-6100. https://doi.org/10.1158/1078-0432.CCR-13-1116
Liu FF, Okunieff P, Bernhard EJ, Stone HB, Yoo S, Norman Coleman C et al. Lessons learned from radiation oncology clinical trials. Clinical Cancer Research. 2013 Nov 15;19(22):6089-6100. https://doi.org/10.1158/1078-0432.CCR-13-1116
Liu, Fei Fei ; Okunieff, Paul ; Bernhard, Eric J. ; Stone, Helen B. ; Yoo, Stephen ; Norman Coleman, C. ; Vikram, Bhadrasain ; Brown, Martin ; Buatti, John ; Guha, Chandan. / Lessons learned from radiation oncology clinical trials. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 22. pp. 6089-6100.
@article{96580b8e7f8a4604a55a321b0ed8dfd4,
title = "Lessons learned from radiation oncology clinical trials",
abstract = "A workshop entitled {"}Lessons Learned from Radiation Oncology Trials{"} was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality and limitations of the preclinical data that supported the hypotheses underlying these trials, and to consider possible solutions to these challenges for the design of future clinical trials. Several themes emerged from the discussions: (i) opportunities to learn from null-hypothesis trials through tissue and imaging studies; (ii) value of preclinical data supporting the design of combinatorial therapies; (iii) significance of validated biomarkers; (iv) necessity of quality assurance in radiotherapy delivery; (v) conduct of sufficiently powered studies to address the central hypotheses; and (vi) importance of publishing results of the trials regardless of the outcome. The fact that well-designed hypothesis-driven clinical trials produce null or negative results is expected given the limitations of trial design and complexities of cancer biology. It is important to understand the reasons underlying such null results, however, to effectively merge the technologic innovations with the rapidly evolving biology for maximal patient benefit through the design of future clinical trials.",
author = "Liu, {Fei Fei} and Paul Okunieff and Bernhard, {Eric J.} and Stone, {Helen B.} and Stephen Yoo and {Norman Coleman}, C. and Bhadrasain Vikram and Martin Brown and John Buatti and Chandan Guha",
year = "2013",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-13-1116",
language = "English (US)",
volume = "19",
pages = "6089--6100",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Lessons learned from radiation oncology clinical trials

AU - Liu, Fei Fei

AU - Okunieff, Paul

AU - Bernhard, Eric J.

AU - Stone, Helen B.

AU - Yoo, Stephen

AU - Norman Coleman, C.

AU - Vikram, Bhadrasain

AU - Brown, Martin

AU - Buatti, John

AU - Guha, Chandan

PY - 2013/11/15

Y1 - 2013/11/15

N2 - A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality and limitations of the preclinical data that supported the hypotheses underlying these trials, and to consider possible solutions to these challenges for the design of future clinical trials. Several themes emerged from the discussions: (i) opportunities to learn from null-hypothesis trials through tissue and imaging studies; (ii) value of preclinical data supporting the design of combinatorial therapies; (iii) significance of validated biomarkers; (iv) necessity of quality assurance in radiotherapy delivery; (v) conduct of sufficiently powered studies to address the central hypotheses; and (vi) importance of publishing results of the trials regardless of the outcome. The fact that well-designed hypothesis-driven clinical trials produce null or negative results is expected given the limitations of trial design and complexities of cancer biology. It is important to understand the reasons underlying such null results, however, to effectively merge the technologic innovations with the rapidly evolving biology for maximal patient benefit through the design of future clinical trials.

AB - A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality and limitations of the preclinical data that supported the hypotheses underlying these trials, and to consider possible solutions to these challenges for the design of future clinical trials. Several themes emerged from the discussions: (i) opportunities to learn from null-hypothesis trials through tissue and imaging studies; (ii) value of preclinical data supporting the design of combinatorial therapies; (iii) significance of validated biomarkers; (iv) necessity of quality assurance in radiotherapy delivery; (v) conduct of sufficiently powered studies to address the central hypotheses; and (vi) importance of publishing results of the trials regardless of the outcome. The fact that well-designed hypothesis-driven clinical trials produce null or negative results is expected given the limitations of trial design and complexities of cancer biology. It is important to understand the reasons underlying such null results, however, to effectively merge the technologic innovations with the rapidly evolving biology for maximal patient benefit through the design of future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84888118737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888118737&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-1116

DO - 10.1158/1078-0432.CCR-13-1116

M3 - Article

VL - 19

SP - 6089

EP - 6100

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -